Embecta Corp. (EMBC)
6.32
-0.13
(-2.02%)
USD |
NASDAQ |
Oct 16, 14:33
Embecta SG&A Expense (TTM) : 319.30M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 319.30M |
| March 31, 2026 | 325.10M |
| December 31, 2025 | 328.50M |
| September 30, 2025 | 332.00M |
| June 30, 2025 | 341.90M |
| March 31, 2025 | 343.20M |
| December 31, 2024 | 355.90M |
| September 30, 2024 | 365.10M |
| June 30, 2024 | 364.00M |
| March 31, 2024 | 365.90M |
| December 31, 2023 | 358.80M |
| Date | Value |
|---|---|
| September 30, 2023 | 341.30M |
| June 30, 2023 | 327.50M |
| March 31, 2023 | 323.70M |
| December 31, 2022 | 305.40M |
| September 30, 2022 | 294.80M |
| June 30, 2022 | 212.90M |
| March 31, 2022 | 189.60M |
| December 31, 2021 | 178.50M |
| September 30, 2021 | 116.30M |
| June 30, 2021 | 116.30M |
| March 31, 2021 | 55.80M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Artivion, Inc. | 254.77M |
| Abbott Laboratories | 13.94B |
| AngioDynamics, Inc. | 116.41M |
| Alphatec Holdings, Inc. | 524.06M |
| AtriCure, Inc. | 323.68M |